Opentrons Labworks Inc., a NYC-based lab platform provider, raised $200M in Series C funding.
SoftBank Vision Fund 2 led the round with participation by Khosla Ventures. Other investors in Opentrons include Sands Capital, Lerer Hippeau Ventures, SOSV, and Y Combinator.
The company intends to use the funds to further invest in its automated lab platform globally. In particular, the investment will support development of new robotic tools, an expanded biofoundry, new diagnostic tests, and additional diagnostic labs.
Led by Jon Brennan-Badal, CEO, Opentrons Labworks develops an integrated lab platform that serves life science and healthcare customers via the Opentrons Robotics, Pandemic Response Lab, and Neochromosome subsidiaries The platform integrates the development of lab robotics, assays, and operations to provide the following industry-specific lab solutions:
- Diagnostic lab services for health systems.
- Lab automation robotics for life science R&D.
- Genome-scale cell engineering for biopharma.
Opentros also added:
- Myrtle Potter, Chair of the Board of Opentrons Labworks, Inc. Myrtle is currently CEO of Sumitovant. Formerly Roivant Sciences, Genentech, BMS, Merck.
- Greg Greeley, President and COO of Opentrons Labworks, Inc. Greg was previously President at Airbnb, the Vice-President of Amazon’s European business, and led Amazon’s Worldwide Prime Program. Greg will be joining the Opentrons Board of Directors.
- Robert S. Langer, Head of Scientific Advisory Board, Neochromosome, Inc. Institute Professor, Massachusetts Institute of Technology. Co-founder of Moderna.
- Jef Boeke, Head of Scientific Advisory Board of PRL, Sol and Judith Bergstein Director for the Institute of System Genetics, and Professor in the Department of Biochemistry and Molecular Pharmacology at NYU Langone. Co-founder of PRL and Neochromosome.
The company is comprised of:
- Opentrons Robotics, a business unit industry leader in flexible, user-friendly lab automation.
- Pandemic Response Lab (PRL), the wholly-owned subsidiary that uses the platform to provide diagnostic lab services to health systems across the US.
- Neochromosome (Neo), a wholly-owned subsidiary of Opentrons that was acquired in March 2021. Neo leverages the Opentrons platform to create genome-scale cell engineering solutions for therapeutics.
- Zenith AI, a wholly-owned subsidiary of Opentrons that was acquired in June 2021. Zenith AI brings proprietary no-code AI and modern machine learning to the Opentrons platform.